قارن بين أفضل أطباء العلاج المناعي مع Keytruda (Pembolizumab) والأسعار في إسرائيل. اعثر على أفضل تطابق لك هنا.
سنختار لك أفضل الأطباء حسب احتياجاتك وميزانيتك.
تمت مراجعة المقالة طبيا من قبل فهد مولود
محرر طبي وعالم بياناتأفضل الأطباء
1
إسرائيل
التقييمات
14000+
من مرضى حقيقيين
قارن أسعار العلاج المناعي مع Keytruda (Pembolizumab) عبر أفضل الدول
اضغط على دولة لعرض أفضل الأطباء والأسعار
احصل على خطط علاجية مخصصة مجانية واختر أفضل خيار. بدون التزام · بدون دفعات لخدماتنا
نائب رئيس قسم الأورام في المركز الطبي رمبام – الدكتور بار سيلا متخصص في أحدث علاجات السرطان.
قد يكون اختيار العيادة في الخارج أمرًا مرهقًا. في Bookimed، حيث ساعدنا أكثر من 800 ألف مريض، نحن نتفهم مخاوفك. نعرف كيفية العثور على الأطباء الموثوقين، وأفضل خيارات الجودة والسعر، وحلول حتى للحالات المعقدة. نحن هنا لإرشادك في كل خطوة على الطريق.
Yan Matsiivskiy
رئيس فريق المنسق الطبي
تم توجيه أكثر من 4300+ رحلة مرضى
3 سنة في Bookimed
142 مريض من Israel وجدوا طبيبهم عبرنا هذا الشهر
اختبار لمدة دقيقتين
أخبرنا بهدفك، ميزانيتك، وخطتك الزمنية
مطابقة بشرية + ذكاء اصطناعي
يجد خوارزمينا التطابقات، ويؤكد المنسق مدى الملاءمة
خياراتك جاهزة
قارن الأسعار، الباقات، والتواريخ. تحدث مع منسقك
تشعر بالحيرة لكثرة الخيارات؟
يوجه علاجك
منسقون شخصيون مدربون طبياً
| الترتيب. | طبيب | خبرة | مناسب لـ | ما الذي يميزهم عن غيرهم | العيادة والموقع | الاستشارة |
|---|---|---|---|---|---|---|
| #1 | علاج مناعي | متخصص في العلاج المناعي باستخدام كيترودا في أحد المراكز الطبية الرائدة في إسرائيل. نائب رئيس قسم الأورام. | إسرائيل | السعر عند الطلب |
Sourasky Medical Center and Hadassah Medical Center lead Israel's immunotherapy landscape with extensive Keytruda programs. These institutions feature dedicated oncology divisions and specialized research units. They provide access to advanced protocols for melanoma, lung cancer, and gastrointestinal malignancies through international clinical trials and expert coordination.
Bookimed Expert Insight: Data shows that Sourasky Medical Center is a premier hub for complex cases due to its multi-disciplinary leadership. Dr. Ido Wolf chairs the National Council for Oncology, while Dr. David Sarid, trained at Oxford, leads clinical trials. This concentration of national leadership and international training allows patients to access treatment plans that align with the latest global standards.
Patient Consensus: Patients note that arriving with your own pathology slides can help avoid diagnostic delays in the busy Tel Aviv centers. Many describe a feeling of deep relief when accessing compassionate-use programs for advanced cancers in Jerusalem. Those who traveled to Israel emphasize that having a coordinator is vital to navigate the hospital bureaucracy quickly.
Israeli oncologists determine Keytruda eligibility by evaluating tumor biomarkers, specific cancer types, and previous treatment results. They prioritize genetic profiling and PD-L1 expression levels to confirm the therapy will be effective. Doctors also check if the patient meets the strict criteria outlined in the national health basket.
Bookimed Expert Insight: Israeli specialists often combine clinical practice with genomic research to refine eligibility. For instance, Dr. Ari Raphael at Sourasky Medical Center serves as a principal investigator for Keytruda clinical trials. This dual role allows doctors to use NGS interpretation and T-cell studies to identify eligibility for patients who might not meet standard criteria. Consultations with experts like Dr. Irina Stepfansky, starting from $750, often include reviews of Phase I-III trial opportunities.
Patient Consensus: Patients note that having clear genetic test results like FoundationOne is essential to avoid treatment denials. They often describe a waiting period for committee approval but find that high PD-L1 levels speed up the process. Many are relieved that doctors also consider compassionate use for complex cases when standard benchmarks are not met.
Bookimed Expert Insight: Data shows that top Israeli oncologists often hold dual research and clinical trial roles. For instance, Dr. David Sarid at Sourasky Medical Center is a principal investigator for clinical trials. This means these doctors often have earlier access to updated protocols for managing complex immunotherapy reactions before they become standard global practice.
Patient Consensus: Patients note their oncologists act as a central figure for infusions and monitoring without transferring care elsewhere. They appreciate that thyroid issues or rashes are handled within the same hospital system. Many feel this approach is much more organized than having to visit separate clinics for every side effect.
You can compare Keytruda doctors in Israel remotely by evaluating their clinical trial leadership, specialized fellowships, and hospital affiliations. Leading oncologists at JCI-accredited centers like Sourasky Medical Center offer video consultations to review genomic profiling and design personalized immunotherapy protocols before you travel.
Bookimed Expert Insight: Data shows a clear distinction between general oncologists and those leading Phase I-III immunotherapy trials. For complex cases, patients should prioritize doctors like Dr. Irina Stepfansky at Sourasky, who directs oncology hospitalization and manages high-level clinical research. These specialists often have earlier access to emerging combination protocols that general practitioners may not yet utilize.
Patient Consensus: Patients note it is helpful to ask doctors specific questions about how many Keytruda cycles they have managed for a particular cancer type. They suggest recording virtual sessions to compare the confidence and phrasing of different specialists side-by-side. Many felt more secure choosing doctors tied to major institutional centers like Hadassah or Sourasky due to their strict training standards.